Immune checkpoint inhibitors: a new class of anticancer drug

Over the past five years, three anticancer drugs (ipilimumab, pembrolizumab and nivolumab) belonging to a new class known as immune checkpoint inhibitors have become available, which are already having an impact on survival in patients with metastatic melanoma and offering promise in the treatment of other malignancies. However, close monitoring for immune‐related adverse events, which can occasionally be severe or fatal, is an important component of treatment.
Source: Prescriber - Category: Primary Care Authors: Tags: Therapy Management Source Type: research